### Tables

1.1 Trends in merger remedies 4
1.2 Distribution of mergers and remedies across broad sectors 6
1.2(a) The case study industries 7
3.1 EC remedy types, 1996–2000 38
3.2 An alternative classification of EC remedy types, 1991–2005 38
3.3 Remedy by type of competition concern 39
3.4 Remedies by theory of harm 39
5.1 NACE 21 pulp, paper and paper products 75
5.2 Merger interventions classified by markets in which remedies imposed 76
5.3 Paper production and consumption by grade, 2001: CEPI classification 77
5.4 Some indicators of structure and performance 79
5.5 Geographical distribution of production by broad product category, leading countries’ shares 80
5.6 European firms in the world’s top 100 81
5.7 Capacity utilization in the graphic paper sector 84
5.8 Main mergers/JV proposals by the largest firms 85
5.9 Leading market shares and concentration in the graphic paper sector 87
5.10 Leading market shares and concentration in the tissues sector 89
5.11 Leading ten market shares in packaging 90
6.1 Dimensions of market, 1994 95
6.2 Estimates of price elasticities for toilet tissue 96
6.3 Number and size distribution of sellers 98
6.4 Advertising spends, 1994 (£000) 100
6.5 Derivation of relative prices in the three segments 103
6.6 Imputing the own-price elasticities 104
6.7 The required comparisons 107
6.8 Theoretical mark-ups pre- and post-merger 109
6.9 Simulated price increases according to diversion ratio 111
6.10 Imputed market shares for individual private labels 112
6.11 Simulation results for toilet tissues 113
Table of Figures

Table 6.12 Simulation results for kitchen towels and facials
Table 6.13 Actual price outcomes
Table 6.14 Actual market shares
Table 6.15 Market structure in 2000 (by volume)
Table 6.16 The required comparisons
Table 6.17 Simulated price increases
Table 7.1 NACE 24.4 manufacture of pharmaceuticals, medicinal chemicals and botanical products
Table 7.1 (a) Anatomical therapeutic chemical classification system
Table 7.1 (b) Typical drug groups as used in the industry (for example, company reports)
Table 7.2 Merger interventions classified by drug type for which remedies were imposed
Table 7.3 Size of the world’s market in pharmaceuticals, 1985–2002
Table 7.3 (a) The member states, the USA and Japan
Table 7.4 The world’s 50 largest pharmaceutical firms, 2002
Table 7.5 The world’s top selling drugs, 2002
Table 7.6 Main mergers by the largest firms
Table 7.7 The impact of mega-mergers on Europe’s top ten in 2002
Table 7.8 US FDA approval timescale
Table 7.9 Regulatory success rates for pipeline products
Table 7.10 Mean number of competitor products per molecule by country
Table 7.11 Importance of elasticities – market share analysis compared with basic simulation (using PCAIDS)
Table 8.1 Pharmaceuticals mergers, markets and simulations
Table 8.2 Market shares for selected CCR markets
Table 8.3 Simulated effect of allowing merger of BM/Roche CCS businesses
Table 8.4 Market shares in immediate-release analgesics in Sweden
Table 8.5 Simulated effect of allowing merger and accepted remedies for PU/Monsanto in immediate-release analgesics in Sweden
Table 8.6 Commercial and scientific names of main products
Table 8.7 AstraZeneca: chirocaine simulations
Table 8.8 Market shares in anti-virals (excluding HIV)
Table 8.9 Simulated effects of unremedied GWSB merger in anti-virals (excluding HIV)
Table 8.10 Market shares in topical anti-virals
Table 8.11 Simulated effects of unremedied GWSB merger in topical anti-virals
Table 9.1 Summary assessment of case study mergers and remedies